Compare GERN & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GERN | NAVI |
|---|---|---|
| Founded | 1990 | 1973 |
| Country | United States | United States |
| Employees | 258 | 670 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 808.3M | 760.4M |
| IPO Year | N/A | N/A |
| Metric | GERN | NAVI |
|---|---|---|
| Price | $1.50 | $8.36 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 3 | 6 |
| Target Price | $2.17 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 14.8M | 1.1M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 6.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | $76.23 |
| Revenue Next Year | $43.75 | $15.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $7.33 |
| 52 Week High | $2.01 | $14.49 |
| Indicator | GERN | NAVI |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 51.01 |
| Support Level | $1.44 | $7.83 |
| Resistance Level | $1.72 | $8.40 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 68.06 | 46.81 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.